Plain language summary of publication of new targets in diabetic retinopathy including a protein called semaphorin 3A: addressing limitations of current treatments.

The purpose of this summary is to explain the findings of a literature review, which is a summary and analysis of scientific discoveries that other researchers have published about a topic. This review looked at treatment approaches in an eye disease that is a common complication of diabetes called diabetic retinopathy (DR). The literature review described how DR can damage the light-sensing area at the back of the eye called the retina. In DR, a damage to blood vessels can impair the normal blood flow to parts of the retina. This condition is what doctors call retinal non-perfusion (RNP). RNP can result in vision loss, seriously affecting people's daily life and activities. Current treatments may help to lessen the severity of DR, but more research is needed to understand how to treat the underlying problem of the reduced blood flow to the retina (RNP) and stop the progression of disease earlier. Current treatments often impose burdens on patients due to side effects, the need for frequent treatment appointments, and pain associated with the administration procedure. New drugs are now being studied to help improve blood flow to the retina and slow or stop sight loss in people with diabetes. Proteins called semaphorin 3A (Sema3A) and neuropilin 1 (Nrp1) regulate blood flow to the retina. New drugs that work against these proteins to help to increase blood flow to the retina are currently being investigated by doctors. Several other drugs that may increase blood flow to the retina are also being studied in animals and humans. Such treatments could protect people's vision and enhance their quality of life over the long term.